Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | AKR1A1 | P14550 | 2/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.43 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4176442 | 0.87 | AKR1A1 (0.46) | AKR1A1AKR1B1ALDH1A1GAAPLA2G7 | |
| SCHEMBL4170549 | 0.87 | ALDH1A1 (0.52) | HPGDALDH1A1GAAPLA2G7LMNA | |
| SCHEMBL4170642 | 0.86 | AKR1B1 (0.42) | HPGDAKR1A1AKR1B1ALDH1A1GAA | |
| SCHEMBL4167292 | 0.84 | PTGDR2 (0.49) | AKR1A1AKR1B1ALDH1A1PTGDR2LMNA | |
| SCHEMBL4164476 | 0.84 | CNR1 (0.51) | AKR1A1AKR1B1ALDH1A1PTGDR2LMNA | |
| SCHEMBL4167818 | 0.83 | AKR1B1 (0.46) | AKR1A1AKR1B1PTGDR2 | |
| SCHEMBL4255735 | 0.82 | TP53 (0.52) | AKR1A1AKR1B1ALDH1A1PTGDR2MAPT | |
| SCHEMBL4167219 | 0.81 | PLA2G7 (0.51) | AKR1A1AKR1B1PLA2G7 | |
| SCHEMBL4169748 | 0.80 | AKR1B1 (0.48) | AKR1A1AKR1B1ALDH1A1PTGDR2LMNA | |
| SCHEMBL4260787 | 0.78 | AKR1B1 (0.48) | AKR1A1AKR1B1ALDH1A1PTGDR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | claimed |
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076049-A1 | Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | TRPV1, TRPV5, TRPV2 | HPGD 989/4885AKR1A1 310/4885AKR1B1 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.